Back

OPTI

-0.99%
NEUTRAL

New SlimBiome® Study Published in Prestigious Journal

Why we think this is neutral

The RNS announcement does not contain any of the mandatory news types, such as contract news, order news, trading update, financing, funding, annual results, asset sale/disposal, flow testing, licence news, or delisting. It simply provides details about a new peer-reviewed study on the company's SlimBiome product. While this is positive news, it does not have a significant impact on the company's financial performance or operations.

Key Points

  • New peer-reviewed study on SlimBiome published in European Journal of Nutrition
  • Study found SlimBiome reduced insulin levels, hunger, and desire to eat, while increasing feelings of fullness
  • Findings support the potential of SlimBiome as a natural approach to weight management

Summary

The healthcare company has announced the publication of a new study on its SlimBiome product in a prestigious scientific journal, providing further evidence of the product's efficacy.

OptiBiotix Health plc (AIM: OPTI), a life sciences company developing products to modify the human microbiome, has announced the publication of a new peer-reviewed study on its SlimBiome product in the European Journal of Nutrition. The study found that a single 3g dose of SlimBiome significantly reduced insulin levels, hunger, and the desire to eat, while increasing feelings of fullness. These findings support the potential of SlimBiome as a natural approach to weight management.

Key Dates

24 June 2025
Presentation of study findings at 18th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health
GENERAL UPDATE